PGL Pharma SRL
PGL Pharma reported total assets of 970,357 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Apr 2026).
The score of PGL Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +39 % Total assets -54 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
PGL Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Apr 2026
- Year ended 31 Dec 2024filed on 04 Jul 2025
- Year ended 31 Dec 2023filed on 26 Jul 2024
- Year ended 31 Dec 2022filed on 30 Jun 2023
PGL Pharma's financial analysis
- Solvency23.3%sector median: 49.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of PGL Pharma
PGL Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0764.558.948
- VAT number
- BE0764558948
- Peppol
- Registered · 0208:0764558948 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 03 Mar 2021
- Registered office
- 4920 Aywaille
- Latest accounts
- 2025 · filed on 30 Apr 2026
- Activity
- Business and other management consultancy activities (NACE 70200)
PGL Pharma (SRL) has been based in Aywaille since 2021, active in: business and other management consultancy activities. For 2025, it reports a net profit of 47,372 € and equity of 226,332 €; its revenue is not published. Its solvency stands at 23.3%, below the median of its sector (49.1%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to PGL Pharma
Companies in the same business, of comparable size and area, outside its group.
- Rednas Invest Business and other management consultancy activities Oosterzele · balance sheet 970,829 €
- iCUBES Business and other management consultancy activities Ghent · balance sheet 969,457 €
- Kendaroy Business and other management consultancy activities Waregem · balance sheet 971,979 €
- PDN Business and other management consultancy activities Antwerp · balance sheet 967,395 €
- BASU Business and other management consultancy activities Haaltert · balance sheet 973,348 €
- Progressus-Corporation Business and other management consultancy activities Ixelles · balance sheet 973,870 €
- JCMK Management Business and other management consultancy activities Braine-l'Alleud · balance sheet 973,888 €
- PSL Consulting Business and other management consultancy activities Antwerp · balance sheet 974,109 €
Frequently asked questions about PGL Pharma
What is the revenue of PGL Pharma?
PGL Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of PGL Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0764558948 for PGL Pharma, if the company is VAT-registered. Its company number (CBE) is 0764.558.948.
Where is the registered office of PGL Pharma?
According to the CBE register, the registered office of PGL Pharma is in 4920 Aywaille.
What is the equity of PGL Pharma?
At the close of the 2025 financial year, the equity of PGL Pharma amounts to 226,332 €, a solvency of 23.3% of total assets.
Who manages PGL Pharma?
The register lists 9 active mandates at PGL Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of PGL Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →